GlassScriptPhysician profile
Eve Marie Gill
NPI 1891842886
$2,107.14
in general payments reported to CMS, 2019-2025
24 companies · $415 in 2025
The $415 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $146 · 2021: $124 · 2022: $260 · 2023: $353 · 2024: $539 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $281.84 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $229.19 | 2019-2025 | |
| Corium, LLC | $229.07 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $210.29 | 2019-2025 | |
| Cranial Technologies, INC | $141.51 | 2019-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $138.65 | 2024-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $115.84 | 2024-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Tris Pharma INC | $105.49 | 2019-2025 | Dyanavel Xr |
| Kaleo, INC. | $100.86 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $89.20 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $58.62 | 2019-2022 | |
| Shire North American Group INC | $55.69 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $49.15 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $48.31 | 2023-2024 | Flumist Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $46.30 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $46.26 | 2024 | |
| Adlon Therapeutics L.P. | $36.20 | 2020-2021 | |
| Neurelis, INC. | $26.32 | 2023 | Valtoco |
| Kyowa Kirin, INC. | $20.32 | 2023 | Crysvita |
| Sobi, INC | $18.46 | 2019 | |
| Seqirus USA INC | $17.52 | 2022 | |
| Glaxosmithkline, LLC. | $14.26 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.16 | 2025 | Zoryve |
| Mylan Pharmaceuticals INC. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eve Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.